Company intelligence / Profile preview
Cellid Co., Ltd.
Seoul, South Koreacellid.co.kr ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Cellid has multiple programs in development with AdCLD-CoV19 for COVID-19 in Phase 3, BVAC-C for head and neck cancer in Phase 1/2, and several other COVID-19 vaccine candidates in preclinical stage.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Immunotherapeutic vaccinesRecombinant vector vaccineProphylactic vaccineTherapeutic vaccine
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on Cellid Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellid Co., Ltd..